Detalhe da pesquisa
1.
Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
J Infect Dis
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38134313